Rilpivirine Hydrochloride
Brand Names: Edurant Ped, Edurant
Methodology & AI Transparency ⓘ
Rilpivirine Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Federal drug listing 59676-280, 59676-278 defines Rilpivirine Hydrochloride (manufactured/labeled by Janssen Products, LP) as a prescription-only oral-route human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor available in 2.5 mg/1 Tablet, for Suspension and 25 mg/1 Tablet, Film Coated for individualized clinical regimens.
- 2 Real-world patient consensus: 84% patient "Worth It" rating across 4 anonymous logs for Rilpivirine Hydrochloride (RxNorm RXN-59676280-2874).
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $47.9974).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Rilpivirine Hydrochloride include nausea (7.3%), headache (7.6%), dizziness (6.4%).
Ask our AI Specialists anything about Rilpivirine Hydrochloride
Rilpivirine Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Federal drug listing 59676-280, 59676-278 defines Rilpivirine Hydrochloride (manufactured/labeled by Janssen Products, LP) as a prescription-only oral-route human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor available in 2.5 mg/1 Tablet, for Suspension and 25 mg/1 Tablet, Film Coated for individualized clinical regimens.
Clinical mechanism for Rilpivirine Hydrochloride (2.5 mg/1 Tablet, for Suspension and 25 mg/1 Tablet, Film Coated, manufactured/labeled by Janssen Products, LP) centers on human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor target modulation following oral-route uptake, maintaining therapeutic plasma exposure across FDA-listed 59676-280, 59676-278 regimens.
Clinical clearance of Rilpivirine Hydrochloride (Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor) relies on mixed metabolic conjugation and unchanged urinary excretion across rilpivirine hydrochloride regimens with a Terminal t½ estimated at 10–23 hrs depending on renal/hepatic reserve (Rilpivirine Hydrochloride) half-life; patients absorbing at F ≈ 48%–60% systemic availability after standard oral Rilpivirine Hydrochloride administration bioavailability typically observe target onset around time to peak concentration spans 1 to 3 hrs under rilpivirine hydrochloride maintenance.
FDA clinical labeling for Rilpivirine Hydrochloride restricts administration in known hypersensitivity to rilpivirine hydrochloride or structurally related human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor compounds; concomitant contra-labeled cyp/transporter therapies during active rilpivirine hydrochloride administration across 2.5 mg/1 Tablet, for Suspension, 25 mg/1 Tablet, Film Coated, with self-reported patient tracking dominated by headache (7.6% of reports), nausea (7.3% of reports), dizziness (6.4% of reports).
Avoid overlapping human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor prescriptions alongside Rilpivirine Hydrochloride to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Rilpivirine Hydrochloride dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Rilpivirine Hydrochloride or structurally related human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor compounds
- Concomitant contra-labeled CYP/transporter therapies during active Rilpivirine Hydrochloride administration
Logged Side-Effect Incidence (4 Reports)
Rilpivirine Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rilpivirine Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation: What a 373-Participant Study Found CAB + RPV LA Q2M was well tolerated and highly effective in maintaining virologic suppression with a low rate of virologic failure. Journal of acquired immune deficiency syndromes (1999) • 2024-08-15 • Phase III Randomized Trial | N = 373 | 87/100 | PMID 38985445 ↗ |
| Can This Approach Help? Inside the Latest Research on Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of In cabotegravir breakthrough experiments, time to breakthrough was similar between L74 and I74 viruses across HIV-1 subtypes B and A6; Q148R was selected at low cabotegravir concentrations. Antimicrobial agents and chemotherapy • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34978890 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, Safety, and how the body absorbs the medicine by Body Mass Index CAB + RPV LA was efficacious and well tolerated, regardless of baseline BMI category. The Journal of infectious diseases • 2024-07-25 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39052748 ↗ |
Rilpivirine Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $47.9974/unit (~$1439.92/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Rilpivirine Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Rilpivirine Hydrochloride RxNorm Concept ID | RXN-59676280-2874 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $47.9974 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 84.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Rilpivirine Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Deterministic Rilpivirine Hydrochloride reference combining NIH RxNorm (RXN-59676280-2874), Medicaid NADAC ($47.9974/unit), and anonymous cohort outcomes (84% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Rilpivirine Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.